Evidence map›Paper›PMID 29016336›Full record

Trial reportThe American journal of tropical medicine and hygiene2017

Efficacy and Safety of a Single-Dose Mebendazole 500 mg Chewable, Rapidly-Disintegrating Tablet for

Steven A Silber, Ermias Diro, Netsanet Workneh, Zeleke Mekonnen, Bruno Levecke, Peter Steinmann, Irenee Umulisa, Hailemaryam Alemu, Benny Baeten, Marc Engelen and 4 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Anthelmintic drugs for treating ascariasis.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Review
  3. Review
  4. An observational assessment of the safety of mass drug administration for trachoma in Ethiopian children.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022
    Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Biological Evaluation of a Potential Anticancer Agent MethylCancer biotherapy & radiopharmaceuticals · 2020
    Article
  11. Trichuriasis.IDCases · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Effectiveness and Tolerability of 3-Day Mebendazole Treatment ofCurrent therapeutic research, clinical and experimental · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Steven A SilberJanssen Research & Development LLC, Raritan, New Jersey.
Ermias DiroUniversity of Gondar, Gondar, Ethiopia.
Netsanet WorknehDepartment of Pediatrics, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia.
Zeleke MekonnenDepartment of Medical Laboratory Sciences and Pathology, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia.
Bruno LeveckeDepartment of Virology, Parasitology and Immunology, Ghent University, Merelbeke, Belgium.
Peter SteinmannUniversity of Basel, Basel, Switzerland.
Irenee UmulisaRwanda Biomedical Centre, Kigali, Rwanda.
Hailemaryam AlemuUniversity of Gondar, Gondar, Ethiopia.
Benny BaetenJanssen Pharmaceutica NV, Beerse, Belgium.
Marc EngelenJanssen Pharmaceutica NV, Beerse, Belgium.
Peter HuJanssen Research & Development LLC, Raritan, New Jersey.
Andrew FriedmanJanssen Research & Development LLC, Raritan, New Jersey.
Alan BasemanJanssen Research & Development LLC, Raritan, New Jersey.
Joseph MrusJanssen Research & Development LLC, Raritan, New Jersey.
Janssen (United States) · USJanssen (Belgium) · BEJimma University · ETUniversity of Gondar · ETGhent University · BERwanda Biomedical Center · RWUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of a new chewable, rapidly-disintegrating mebendazole (MBZ) 500 mg tablet for

Indexed as

AdolescentAnimalsAntinematodal AgentsAscariasisAscaris lumbricoidesChildChild, PreschoolDose-Response Relationship, DrugDouble-Blind MethodEthiopiaFecesFemaleHumansInfantMaleMebendazoleAntinematodal AgentsMebendazoleTablets

Identifiers

PMID29016336
PMCPMC5805036
OpenAlexW2752306600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.